Albany, NY -- (SBWIRE) -- 03/08/2019 -- Idiopathic Pulmonary Fibrosis - Epidemiology and Market Forecast-2028

The total diagnosed prevalent population of Idiopathic pulmonary fibrosis in 7 major markets were found to be approximately 265,394 cases in 2017.

1. The higher diagnosed prevalent cases of IPF in the United States was 101,736 in 2017, followed by EU5 and Japan
2. Among the EU5 countries, Germany has the highest diagnosed prevalent population of IPF with 37,912 cases, followed by France. Spain has the lowest prevalent cases.
3. Idiopathic pulmonary fibrosis is further segmented on the basis of severity as mild, moderate and severe.

(Albany, US) DelveInsight launched a new report on Idiopathic Pulmonary Fibrosis - Market Insights, Epidemiology and Market Forecast-2028

Key topics covered

1. This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Idiopathic Pulmonary Fibrosis market.
2. Organize sales and marketing efforts by identifying the best opportunities for Idiopathic Pulmonary Fibrosis market.
3. To understand the future market competition in the Idiopathic Pulmonary Fibrosis market.

"The European 5 countries and the United States accounted for the 56.8% and 38.3% respectively, of the total diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis cases in the 7 major markets in 2017."
Request for sample pages

Global burden of Idiopathic Pulmonary Fibrosis (IPF) has increased over the years. Among the 7 major markets, the United States has reported having maximum diagnosed prevalent cases of IPF. The therapeutic market of Idiopathic Pulmonary Fibrosis in the seven major markets was around USD 1,700 million in 2017, and expected to grow during the study period (2017-2028).

United States is expected to grab the highest market share of 2028 IPF market with around USD 1100 million. Among EU5 countries, Germany has the highest market size with around USD 182 million in 2017, while the United Kingdom has the lowest market size of IPF with around USD 50 million in 2017.

IPF is a progressive debilitating disease, with no available cure. With the lack of any approved therapy, the current Idiopathic pulmonary fibrosis market is dominated with supportive therapies mainly (systemic corticosteroids, immunosuppressant drugs and tyrosine kinase inhibitors) and approved anti fibrotic drugs. The current therapeutic market of IPF is dependent on Nintedanib and Pirfenidone, targeting mild to moderate segment of the patient population.

Companies covered
1. FibroGen
2. Pliant Therapeutics
3. Kadmon Corporation LLC
4. Promedior, Inc.
5. MediciNova
And many others

Drugs covered

1. Pemrevlumab
2. PLN-74809
3. KD025
4. PRM151
5. Tipelukast
And many others

Table of contents
1. Key Insights
2. Idiopathic Pulmonary Fibrosis Market Overview at a Glance
3. Idiopathic Pulmonary Fibrosis Disease Background and Overview
1. Introduction
4.1. Key Findings
4.2. Idiopathic Pulmonary Fibrosis 7 MM Prevalent Population
4.3. Idiopathic Pulmonary Fibrosis Country Wise-Epidemiology
4.3.1. United States
4.3.2. EU5
4.3.2.1. France
4.3.2.2. Germany
4.3.2.3. Italy
4.3.2.4. Spain
4.3.2.5. United Kingdom
4.3 Japan
5. Current Treatment Practices
6. Unmet needs
7. Marketed Products
7.1. Esbriet (Pirfenidone): InterMune Inc.
7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG
8. Emerging Therapies
9. Key Cross Competition
10. Phase III Drugs
10.1. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation
11. Phase II Drugs
11.2. Gefapixant: Merck & Co., Inc.
11.3. GLPG1690: Galapagos NV
11.4. LT-1001: LTT Bio-Pharma
11.5. BG00011: Biogen Inc.
11.6. BMS-986020: Bristol-Myers Squibb
11.7. LT-1002: Chong Kun Dang Pharmaceutical
11.8. Pamrevlumab: FibroGen
11.9. PBI4050: ProMetic Life Sciences
11.10. PRM 151: Promedior, Inc.
11.11. Tipelukast: MediciNova
11.12. TD139: Bristol-Myers Squibb
11.13. VAY736: Novartis
11.14. TAS-115: Taiho Pharmaceutical
12. IPF: Market Analysis
13. Market Size of IPF by Country
13.2. EU5 Market Outlook
13.3. Germany
13.4. France
13.5. Italy
13.6. United Kingdom
13.7. Spain
13.8. Japan: Market Analysis
14. Market Drivers of IPF
15. Market Barriers of IPF
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight